Isis Pharmaceuticals announced that it has initiated a Phase 1 clinical study for ISIS-APOARx, an antisense drug targeting apolipoprotein(a) for the treatment of atherosclerosis. Apolipoprotein contributes to the formation of plaque in arteries through its attachment to an LDL-C particle in a complex termed lipoprotein. High levels of lipoprotein are associated with an increased risk of atherosclerosis, coronary heart disease, heart attack and stroke. ISIS-APOARx is designed to reduce lipoprotein by inhibiting the production of apolipoprotein. Isis plans to develop ISIS-APOARx to treat patients with high Lp(a) levels who are at high risk of experiencing cardiovascular events.